Copyright
©The Author(s) 2016.
World J Gastroenterol. Jun 14, 2016; 22(22): 5143-5153
Published online Jun 14, 2016. doi: 10.3748/wjg.v22.i22.5143
Published online Jun 14, 2016. doi: 10.3748/wjg.v22.i22.5143
Table 1 Seroprevalence of hepatitis E virus in different population groups in Iran
Study population | City or province | Location | Year of study | No. of participants | Age, mean ± SD (age group), yr | No. of positive cases | HEV seroprevalence | HEV diagnosis | Manufacturer of Serology kits | Ref. |
General population | Nahavand | West | 2003 | 1824 | 34.7 ± 19.5 (6 to > 70) | 170 | 9.3% | Anti-HEV IgG | DIA.PRO, Italy | Taremi et al[42] |
General population | Sari, Mazandaran | North | 2003 | 1080 | 2 to 25 | 25 | 2.3% | Anti-HEV IgG | DIA.PRO, Italy | Saffar et al[43] |
General population | Tehran and Golestan | North-Center | 2006 | 1423 | 37.9 ± 13.4 (18 to 65) | 105 | 7.4% | Anti-HEV total antibodies | DIA.PRO, Italy | Sepanlou et al[39] |
North-East | ||||||||||
General population | Shiraz | South | 2011-2012 | 1030 | < 1 to 95 | 138 | 13.4% | Anti-HEV total antibodies | DIA.PRO, Italy | Asaei et al[40] |
9 | 0.9% | Anti-HEV IgM | ||||||||
General population | Mashhad | North-East | 2009 | 1582 | 29.06 ± 18.513 (1 to 90) | 225 | 14.2% | Anti-HEV total antibodies | DIA.PRO, Italy | Ahmadi Ghezeldasht et al[35] |
General population | Isfahan | Center | 2005 | 816 | 6 to > 50 | 3.8% | Anti-HEV total antibodies | DIA.PRO, Italy | Ataei et al[41] | |
General population | Tehran | North-Center | 2006-2007 | 551 | 41.28 ± 16.96 (1 to 83) | 51 | 9.3% | Anti-HEV IgG | DIA.PRO, Italy | Mohebbi et al[44] |
General population | Ahvaz | South-West | 2014 | 510 | 45.89 ± 14.63 (18 to 81) | 235 | 46.1% | Anti-HEV IgG | DIA.PRO, Italy | Farshadpour et al[36] |
7 | 1.4% | Anti-HEV IgM | ||||||||
General population | Khorramabad | West | 2009 | 400 | 36 (> 20) | 31 | 7.8% | Anti-HEV total antibodies | (ND) | Raoofi et al[45] |
Soldier | Tehran | North-Center | 2006 | 800 | 19 ± 1.2 (17 to 23) | 9 | 1.1% | Anti-HEV IgG | DIA.PRO, Italy | Ghorbani et al[46] |
0.0% | Anti-HEV IgM | |||||||||
Blood donor | Khuzestan | South-West | 2005 | 400 | 33.3 (18 to 60) | 46 | 11.5% | Anti-HEV IgG | HEV-EIA, Biokit, Spain | Assarehzadegan et al[55] |
Blood donor | Tehran | North-Center | 2003-2004 | 90 | 31.8 ± 11 | 7 | 7.8% | Anti-HEV total antibodies | DIA.PRO, Italy | Aminiafshar et al[54] |
Blood donor | Tabriz | North-West | 2004 | 399 | 31.4 ± 9.8 | 31 | 7.8% | Anti-HEV IgG | DIA.PRO, Italy | Taremi et al[49] |
Blood donor | Markazi | West-Center | 2012 | 530 | 36.3 ± 11.7 (18 to 71) | 76 | 14.3% | Anti-HEV IgG | DIA.PRO, Italy | Ehteram et al[53] |
Blood donor | Kerman | South-East | 2007-2008 | 400 | 20 to 60 | 31 | 7.7% | Anti-HEV IgG | DIA.PRO, Italy | Arabzadeh et al[52] |
Blood donor | Tehran | North-Center | 2014 | 559 | 38 (18 to > 47) | 45 | 8.1% | Anti-HEV IgG | DIA.PRO, Italy | Hesamizadeh et al[50] |
Blood donor | Tehran | North-Center | ND | 200 | 20 to 61 | 9 | 4.5% | Anti-HEV antibodies | DRG, Diagnostics,Germany | Keyvani et al[51] |
Drug users (addicts) | Hamadan | West | 2011-2012 | 131 (IDUs) | 35.57 ± 8.13 (22 to 70) | 8 | 6.1% | Anti-HEV IgG | DIA.PRO, Italy | Keramat et al[58] |
131 (non-IDUs) | 31.57 ± 8.19 (20 to 45) | 2 | 1.5% | |||||||
Drug users | Ahvaz | South-West | 2005-2006 | 228 | 34.1 ± 6.1 (18 to 54) | 35 | 15.4% | Anti-HEV IgG | DIA.PRO, Italy | Alavi et al[57] |
114 (IDUs) | 26 | 22.8% | ||||||||
66 (Inhalant) | 6 | 9.1% | ||||||||
48 (Oral opiate) | 3 | 6.2% | ||||||||
Hemodialysis | Hamadan | West | 2010 | 153 | < 20 to > 60 | 30 | 19.2% | Anti-HEV IgG | DIA.PRO, Italy | Eini et al[63] |
Hemodialysis | Tabriz | North-West | 2004 | 324 | 53.5 ± 15.1 | 24 | 7.4% | Anti-HEV IgG | DIA.PRO, Italy | Taremi et al[64] |
Hemodialysis | Jahrom | South | 2007 | 43 | 59.3 ± 14.4 | 3 | 7.0% | Anti-HEV IgG | DIA.PRO, Italy | Pourahmad et al[65] |
Hemodialysis | Zanjan | West | 2011 | 93 | 57.0 ± 18.5 (16 to 88) | 25 | 26.9% | Anti-HEV total antibodies | DIA.PRO, Italy | Mobaien et al[66] |
Hemodialysis | Jahrom and Shiraz | South | 2010 | 80 | 55.69 ± 14.70 (26 to 80) | 5 | 6.3% | Anti-HEV IgG | DIA.PRO, Italy | Zekavat et al[67] |
Hemodialysis | Ahvaz | South-West | ND | 47 | 55.27 ± 8.1 | 5 | 10.6% | Anti-HEV IgG | DIA.PRO, Italy | Beladi Mousavi et al[68] |
Hemodialysis | Isfahan | Center | 2012 | 274 | 59.9 ± 16.4 (21 to 80) | 78 | 28.3% | Anti-HEV IgG | DIA.PRO, Italy | Alavian et al[69] |
HCV-infected patients | Tehran | North-Center | ND | 100 | 20 to 61 | 7 | 7% | Anti-HEV antibodies | DRG, Diagnostics, Germany | Keyvani et al[51] |
HBV-infected patients | Tehran | North-Center | ND | 150 | 20 to 61 | 17 | 11.3% | Anti-HEV antibodies | DRG, Diagnostics, Germany | Keyvani et al[51] |
Thalassemia patients with chronic hepatitis C | Iran | Iran | 2009-2010 | 64 | 25.08 ± 6.46 (12 to 76) | 1 | 1.6% | Anti-HEV IgG | DIA.PRO, Italy | Karimi Elizee et al[56] |
Hemophilia patients with chronic hepatitis C | Iran | Iran | 2009-2010 | 155 | 30.63 ± 11.51 (12 to 76) | 5 | 3.2% | Anti-HEV IgG | DIA.PRO, Italy | Karimi Elizee et al[56] |
GB Virus C positive hemodialysis patients | Gorgan | North-East | 2012 | 22 | 54.32 ± 12.56 | 0 | 0.0% | total anti-HEV | DIA.PRO, Italy | Kelishadi et al[77] |
patients with chronic liver disease | Azerbaijan | North-West | 2005-2006 | 200 | 48.26 ± 18.19 (10 to 87) | 55 | 27.5% | Anti-HEV IgG | DIA.PRO, Italy | Somi et al[78] |
HIV-infected patients | Tehran | North-Center | 2012 | 100 | 38 | 10 | 10% | Anti-HEV IgG | DIA.PRO, Italy | Ramezani et al[79] |
0 | 0.0% | Anti-HEV IgM | ||||||||
0 | 0.0% | HEV RNA | ||||||||
HIV-infected patients | Shiraz | South | 2013 | 158 | 39.1 ± 8 | 26 | 16.4% | Anti-HEV total antibodies | DIA.PRO, Italy | Joulaei et al[80] |
Kidney transplant recipient patients | Urmia | North-West | 1991-2010 | 91 | 35.4 ± 14.5 (6 to 65) | 28 | 30.8% | Anti-HEV IgG | DIA.PRO, Italy | Rostamzadeh Khameneh et al[81] |
- Citation: Taherkhani R, Farshadpour F. Epidemiology of hepatitis E virus in Iran. World J Gastroenterol 2016; 22(22): 5143-5153
- URL: https://www.wjgnet.com/1007-9327/full/v22/i22/5143.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i22.5143